Intrahepatic cholangiocarcinoma

This phase 2 trial tests whether a combination of three treatments can shrink inoperable intrahepatic cholangiocarcinoma (a type of bile duct cancer) enough to allow surgical removal. The approach delivers chemotherapy directly into the liver's blood supply (HAIC) along with the …

Researchers are testing a combination treatment for intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. The study gives participants Y-90 radioembolization, which delivers radiation directly to liver tumors, followed by six cycles of the che…

This early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…

This study looks at whether adding radiation to the liver can improve outcomes for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that has spread. About 60 adults with at least one liver tumor 3 cm or larger will receive either standard therapy a…

This phase II trial is testing whether alternating standard chemotherapy and immunotherapy with a targeted drug called pemigatinib can help people with advanced biliary tract cancers that have FGFR2 alterations. The study includes adults with cancer that cannot be removed by surg…

This phase 2 trial tests whether a series of procedures to remove cancerous tumors, given one after another, can improve outcomes for people with stage IV foregut cancers (like stomach, pancreas, or bile duct cancer) who have no detectable cancer DNA in their blood after initial …

This study tests whether adding an immune-boosting drug (PDS01ADC) to standard chemotherapy delivered directly to the liver can help people with colorectal, bile duct, or adrenal cancer that has spread to the liver. About 70 adults will receive the drug combination along with a s…

This study tests whether combining two drugs (pemigatinib and durvalumab) can shrink or control advanced bile duct cancer that has a specific FGFR2 gene change. About 38 adults whose cancer has not responded to prior treatment will receive daily pills and an IV infusion every 3 w…

This trial tests an inhaled biologic called YSCH-01 in people with advanced non-small cell lung cancer or advanced solid tumors that have spread to the lungs. The study aims to find the safest dose and see if the treatment can shrink tumors or slow the disease. Participants inhal…

This study tests a new drug called ivonescimab against standard chemotherapy (FOLFOX) for people with advanced bile duct cancer that has worsened after initial treatment. About 72 participants who were in the SAFIR-ABC10 trial will be randomly assigned to receive either ivonescim…

This global Phase 3 trial is testing whether adding the experimental immunotherapy rilvegostomig to standard chemotherapy helps people with advanced biliary tract cancer live longer, compared to adding the approved drug durvalumab. About 1,100 participants with inoperable or meta…

This study compares standard chemotherapy (gemcitabine and oxaliplatin) alone versus the same drugs plus a liver-directed chemotherapy (HAI FUDR/dexamethasone) in people with bile duct cancer that has spread within the liver but cannot be removed surgically. About 164 adults with…

This trial tests whether phycocyanin, a natural protein from spirulina, can reduce liver injury and support recovery in adults having part of their liver removed due to intrahepatic cholangiocarcinoma. About 30 participants will take either phycocyanin or a placebo daily for thre…

This study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…

This early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…

This phase II trial is testing whether freezing tumors (cryoablation) before giving an experimental immunotherapy drug called rilafup α along with standard chemotherapy can help shrink or control advanced bile duct and gallbladder cancers. The study enrolls 30 people who have not…

This study tests whether combining chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab) and a targeted radiation treatment (Yttrium-90 microspheres) can shrink tumors in people with locally advanced bile duct cancer that cannot be removed by surgery. T…

This study tests a combination of two drugs, GNS561 and trametinib, in people with advanced bile duct cancer that has a specific genetic change (KRAS mutation) and has not responded to standard first-line therapy. The trial has two phases: first to find the safest dose, then to s…

This study tests a new approach for people with advanced liver cancer that cannot be surgically removed. Participants receive radiation followed by an injection of their own specially trained immune cells (dendritic cells), a pneumonia vaccine to boost immunity, and immunotherapy…

This study tests a new drug called ALE.P03 in adults with advanced or metastatic solid tumors that have a specific protein (Claudin-1) on their surface. The drug is an antibody-drug conjugate designed to deliver a toxic payload directly to cancer cells. The trial has two phases: …

This study tests whether adding a targeted, tumor-destroying treatment (like focused radiation or heat ablation) can help people with certain gastrointestinal cancers—such as colorectal, small bowel, or pancreatic cancer—continue their current systemic therapy longer when only a …

This study tests a combination of two drugs (apatinib and adebrelimab) plus chemotherapy (GEMOX) as a first treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The goal is to see if this mix shrinks tum…

This study tests a new therapy called EB-HC01, which uses specially engineered natural killer (NK) immune cells to attack cancer cells that have two specific markers (HER2 and CEACAM5). The trial enrolls adults with advanced bile duct or gallbladder cancers that have worsened aft…

This study tests whether adding immunotherapy (adebrelimab) to different chemotherapy or targeted therapy regimens can help prevent cancer recurrence in people with intrahepatic cholangiocarcinoma who have a high risk of the cancer coming back after surgery. About 90 participants…

This early-phase study tests a new cell therapy for people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not responded to standard treatments. The therapy uses the patient's own immune T cells, enhanced with a protein called CD160 to better target …

This study tests two surgical techniques for bile duct cancer that has spread to nearby lymph nodes. One method removes the bile duct completely to take out all affected lymph nodes, while the other leaves the bile duct in place but may leave some lymph tissue behind. The goal is…

This phase 3 trial is testing whether giving a targeted therapy after initial standard chemotherapy can help people with advanced biliary cancer live longer without their disease getting worse. Participants must have a tumor with a specific genetic change and stable disease after…

This early-phase trial is testing whether combining a targeted radiation treatment (Y90 radioembolization) with two immunotherapy drugs (durvalumab and tremelimumab) is safe and shows promise for people with bile duct cancer that cannot be removed by surgery. The study will enrol…

This study is testing a treatment strategy for biliary tract cancer, a group of aggressive cancers with poor survival. The approach combines hepatic arterial infusion chemotherapy (HAIC) with systemic drugs like bevacizumab and an immunotherapy. The goal is to shrink tumors and i…

This study tests a new combination of drugs for people with advanced intrahepatic cholangiocarcinoma, a type of liver cancer that cannot be removed by surgery. About 35 participants will receive an oral drug called chidamide along with standard chemotherapy and immunotherapy. The…

This phase 2 trial is testing a combination of radiation beads (Y-90), immunotherapy (durvalumab), and chemotherapy (gemcitabine and cisplatin) in 30 people with advanced bile duct cancer that cannot be removed surgically. The goal is to see if this mix can slow cancer growth and…

This study tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy (gemcitabine and cisplatin) before and after surgery can improve outcomes for people with a type of bile duct cancer called intrahepatic cholangiocarcinoma. The trial will enroll 24 adul…

This study tests a new method to check if a liver cancer treatment called radioembolization is safe for the lungs. Currently, doctors use a test particle (MAA) to estimate lung radiation risk, but it may not be perfectly accurate. The new method uses a small 'scout dose' of the a…

This study tests whether a liver transplant after a combination of targeted internal radiation (SIRT with Yttrium-90) and chemotherapy can improve 3-year survival in people with locally advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer) that cannot be surgicall…

This study tests a new combination of four drugs—two standard chemotherapies plus an immunotherapy and a cholesterol drug—in people with advanced bile duct cancer. All 29 participants will receive the same treatment. Researchers will check how many patients see their tumors shrin…

This study looks at whether a liver transplant can help people with a certain type of advanced bile duct cancer that hasn't spread. Participants will first receive chemotherapy to control the cancer, then undergo a liver transplant. The goal is to see if this approach helps them …

This study tests a new first-line treatment for people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer that cannot be removed by surgery. The treatment combines chemotherapy directly into the liver artery (HAIC) with two drugs: durvalumab (an immunothera…

This study is testing a new way to deliver radiation therapy for liver cancer. Instead of multiple sessions over weeks, patients receive a single, high-dose treatment guided by real-time MRI scans. The approach aims to be more precise and convenient. The trial will enroll 62 adul…

This study tests two treatments for a type of bile duct cancer that cannot be surgically removed. One delivers chemotherapy directly to the liver through a pump, and the other uses tiny radioactive beads injected into the tumor's blood supply. Both are given alongside standard ch…

This study tests a pump that delivers chemotherapy directly to the liver for people with colorectal cancer or bile duct cancer that has spread to the liver. The goal is to see if the pump is safe and if patients can get their pump refilled at a local clinic instead of always trav…

This study tests a treatment for people with advanced bile duct cancer (ICC) that cannot be removed by surgery. The treatment combines chemotherapy given directly into the liver (HAIC) with immunotherapy drugs. The goal is to see if this combination can shrink tumors enough to al…

This study tests giving chemotherapy drugs (gemcitabine and oxaliplatin) directly into the liver's main artery for people with advanced bile duct cancer that hasn't spread elsewhere. The goal is to shrink tumors while reducing side effects. About 40 adults who have already tried …

This study tests an experimental drug called HMPL-453 in people with advanced intrahepatic cholangiocarcinoma, a type of bile duct cancer, that has a specific genetic change (FGFR2 fusion). The trial aims to see how well the drug shrinks tumors. About 235 adults will take the dru…

This phase 2 trial is testing whether adding the immunotherapy drug pembrolizumab to standard chemotherapy or the targeted drug lenvatinib can help people with advanced biliary tract cancer live longer and control their tumors better. The study will enroll 60 adults whose cancer …

This early-phase study tests whether adding heat therapy and a special type of radiation to standard chemoimmunotherapy is safe and feasible for people with advanced bile duct cancer that cannot be removed by surgery. About 15 participants will receive the combination treatment. …

This phase 2 trial is testing whether adding two immunotherapy drugs (tuvonralimab and iparomlimab) to standard chemotherapy before surgery can improve outcomes for people with bile duct or gallbladder cancer. About 45 adults with resectable or borderline-resectable cancer will r…

This early-phase trial is testing a new therapy called Meta10-TIL for people with advanced solid tumors that have not responded to at least one prior treatment. The therapy uses a patient's own tumor-fighting immune cells, which are modified in the lab to work better, and then gi…

This study tests a combination of four drugs—gemcitabine, cisplatin, nab-paclitaxel, and tislelizumab—in people with advanced biliary tract cancer (bile duct or gallbladder cancer) that has not been treated before. The goal is to see if this mix can shrink tumors and improve surv…

This study aims to develop a simple blood test that can tell the difference between two common types of liver cancer: hepatocellular carcinoma and cholangiocarcinoma. Researchers will analyze tiny particles called exosomes in the blood using machine learning. The goal is to help …

This pilot study is testing a new radioactive tracer called 89Zr-TLX250, which targets a protein (CAIX) found on certain tumor cells. The goal is to see if PET-CT scans using this tracer can detect more tumor lesions in people with liver cancer, bile duct cancer, or neuroendocrin…

This study looks at whether a new type of PET scan (FAPI PET/CT) can find and stage gallbladder and bile duct cancers better than the standard scan. About 60 adults with suspected or confirmed cancer will get both scans to compare accuracy. The goal is to improve detection of can…

This study is testing a blood test that looks for DNA changes from tumors to help diagnose and manage biliary tract cancers, which are often found late and have a low survival rate. Researchers will enroll 1,800 participants with confirmed cancers to see how accurate the test is.…

This study looks at whether an improved endoscopic ultrasound (EUS) can better find cancer in lymph nodes of people with bile duct cancer. About 250 patients with presumed resectable cancer will get the enhanced EUS before surgery. The goal is to see how many patients are spared …

This study follows 150 adults with liver or bile duct cancer who are receiving standard treatments like surgery, ablation, or chemotherapy. Researchers will collect repeated blood samples before, during, and after treatment to analyze tumor DNA, immune cells, and proteins. The go…

This study looks at whether CT scans can help doctors predict how well chemotherapy will work for people with pancreatic or liver cancer. About 259 adults with these cancers will get CT scans before and during treatment. The goal is to see if changes in the scan can tell if the t…

This study tests whether people with liver cancer can be safely treated as outpatients instead of staying in the hospital after a procedure that delivers treatment directly to the liver's blood supply. About 206 patients will be randomly assigned to either outpatient or standard …

This study looks at whether the amount of healthy liver removed during surgery can predict liver failure afterward. Researchers will create a risk model based on 1,600 patients who had liver surgery for cancer. The goal is to help doctors identify high-risk patients before surger…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find genetic changes in advanced bile duct cancer as well as a traditional tissue biopsy. The goal is to make it easier and less invasive to identify which patients might benefit from targeted therapi…

This study looks at whether emotional disorders like depression and anxiety affect how well immunotherapy works in people with liver cancer. Researchers will follow 651 patients and compare treatment outcomes between those with and without emotional distress. The goal is to under…